Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2017, there were 488,800 incident cases of esophageal cancer worldwide, and expects that number to increase to 534,700 incident cases by 2026.
- Incidence is higher in males compared to females, and is highest in the Asia region. Photofrin, a two-step therapy that involves the injection of the photoactive drug followed by drug activation using laser therapy, is the only FDA-approved drug for esophageal cancer.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs in mid-to-latestage development are administered intravenously, with three drugs being tested in oral formulations.
- The only high-impact upcoming event in the esophageal cancer space is topline Phase III trial results for Opdivo. The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 40.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 10 licensing and asset acquisition deals involving esophageal cancer drugs during 2014–19. The $1,456m drug development collaboration agreement signed in 2015 between Eli Lilly and Innovent Biologics to support the development and potential commercialization of at least three cancer treatments was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 89 trials.
- Roche and Sanofi lead industry sponsors with the highest number of clinical trials for esophageal cancer.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Keytruda for Esophageal Cancer (January 14, 2019)
25 Opdivo for Esophageal Cancer (January 9, 2019)
27 Keytruda for Esophageal Cancer (November 14, 2018)
28 Keytruda for Esophageal Cancer (June 3, 2018)
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Chugai Acquires Selected Rights to Oncolys’ Telomelysin
32 Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
35 PARENT PATENTS
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
40 BIBLIOGRAPHY
40 Prescription information
41 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2017–26
14 Figure 2: Incident cases of esophageal cancer, by gender, 2017
17 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
18 Figure 4: Pipeline drugs for esophageal cancer, by company
18 Figure 5: Pipeline drugs for esophageal cancer, by drug type
18 Figure 6: Pipeline drugs for esophageal cancer, by classification
25 Figure 7: Keytruda for Esophageal Cancer (January 14, 2019): Phase III – KEYNOTE-181
27 Figure 8: Opdivo for Esophageal Cancer (January 9, 2019): Phase III – ATTRACTION-3
28 Figure 9: Keytruda for Esophageal Cancer (November 14, 2018): Phase III – KEYNOTE-181
30 Figure 10: Keytruda for Esophageal Cancer (June 3, 2018): Phase II – KEYNOTE-180
31 Figure 11: Key upcoming events in esophageal cancer
33 Figure 12: Probability of success in the esophageal cancer pipeline
34 Figure 13: Licensing and asset acquisition deals in esophageal cancer, 2014–19
35 Figure 14: Parent patents in esophageal cancer
36 Figure 15: Clinical trials in esophageal cancer
36 Figure 16: Top 10 drugs for clinical trials in esophageal cancer
37 Figure 17: Top 10 companies for clinical trials in esophageal cancer
37 Figure 18: Trial locations in esophageal cancer
38 Figure 19: Esophageal cancer trials status
39 Figure 20: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2017–26
16 Table 2: Marketed drugs for esophageal cancer
20 Table 3: Pipeline drugs for esophageal cancer in the US
24 Table 4: Keytruda for Esophageal Cancer (January 14, 2019)
26 Table 5: Opdivo for Esophageal Cancer (January 9, 2019)
27 Table 6: Keytruda for Esophageal Cancer (November 14, 2018)
29 Table 7: Keytruda for Esophageal Cancer (June 3, 2018)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the